Skip to content
myglp1coverage.com

BCBS Louisiana · Type 2 Diabetes

BCBS Louisiana coverage for Mounjaro (Type 2 Diabetes)

Employer / Commercial Insurance

Covered (preferred drug)

What you need to qualify

  • Age 10 and older
  • A1C of 6.5% or higher
  • Lab results confirming eligibility

Qualification pathways

You can qualify through any one of these.

Initial approval for T2DM

All of:

  • Diagnosis of type 2 diabetes mellitus
  • Patient is 10 years of age or older

Plus any one of:

  • HbA1c >= 6.5% (from accredited laboratory; point-of-care testing not acceptable)
  • Fasting plasma glucose (FPG) >= 126 mg/dL (from accredited laboratory; point-of-care testing not acceptable)
  • 2-hour plasma glucose (2-h PG) >= 200 mg/dL (from accredited laboratory; point-of-care testing not acceptable)

Documentation to bring

  • Documentation confirming diagnosis of type 2 diabetes mellitus
  • Lab result from accredited laboratory (not point-of-care) showing HbA1c >= 6.5%, FPG >= 126 mg/dL, or 2-h PG >= 200 mg/dL
  • Documentation that patient is 10 years of age or older

Not covered when

  • Use in patients younger than 10 years of age is considered investigational
  • Use for any non-FDA approved indication is considered investigational

Policy note: Mounjaro is listed as a preferred product. Laboratory testing must be performed by an accredited laboratory; point-of-care testing is not acceptable for confirming diagnosis. Wegovy (semaglutide) is addressed separately in medical policy 00886 and is not covered by this policy. This policy focuses on GLP-1/GIP agonists for diabetes only.

Policy effective May 1, 2026 · verified June 2, 2026 · source: GLP1AgonistsforDiabetes.pdf

ACA Marketplace

Covered (preferred drug)

What you need to qualify

  • Age 10 and older
  • A1C of 6.5% or higher
  • Lab results confirming eligibility

Qualification pathways

You can qualify through any one of these.

Initial approval for T2DM

All of:

  • Diagnosis of type 2 diabetes mellitus
  • Patient is 10 years of age or older

Plus any one of:

  • HbA1c >= 6.5% (from accredited laboratory; point-of-care testing not acceptable)
  • Fasting plasma glucose (FPG) >= 126 mg/dL (from accredited laboratory; point-of-care testing not acceptable)
  • 2-hour plasma glucose (2-h PG) >= 200 mg/dL (from accredited laboratory; point-of-care testing not acceptable)

Documentation to bring

  • Documentation confirming diagnosis of type 2 diabetes mellitus
  • Lab result from accredited laboratory (not point-of-care) showing HbA1c >= 6.5%, FPG >= 126 mg/dL, or 2-h PG >= 200 mg/dL
  • Documentation that patient is 10 years of age or older

Not covered when

  • Use in patients younger than 10 years of age is considered investigational
  • Use for any non-FDA approved indication is considered investigational

Policy note: Mounjaro is listed as a preferred product. Laboratory testing must be performed by an accredited laboratory; point-of-care testing is not acceptable for confirming diagnosis. Wegovy (semaglutide) is addressed separately in medical policy 00886 and is not covered by this policy. This policy focuses on GLP-1/GIP agonists for diabetes only.

Policy effective May 1, 2026 · verified June 2, 2026 · source: GLP1AgonistsforDiabetes.pdf

All Mounjaro policies under BCBS Louisiana · Check your card